​

Genmab (GMAB) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

GMAB Stock Forecast

Genmab (GMAB) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $39.08, with a high of $43.00 and a low of $32.00. This represents a 36.45% increase from the last price of $28.64.

$20 $25 $30 $35 $40 $45 High: $43 Avg: $39.08 Low: $32 Last Closed Price: $28.64

GMAB Stock Rating

Genmab stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (72.22%), 4 Hold (22.22%), 1 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 1 4 13 Strong Sell Sell Hold Buy Strong Buy

GMAB Price Target Upside V Benchmarks

TypeNameUpside
StockGenmab36.45%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1212
Avg Price Target$43.00$41.50$40.63
Last Closing Price$28.64$28.64$28.64
Upside/Downside50.14%44.90%41.86%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26-92--11
Jun, 26-92--11
May, 26-92--11
Apr, 26-83--11
Mar, 26-63--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 22, 2026New Street$43.00$28.3751.57%50.14%
May 27, 2026Gregory RenzaTruist Financial$40.00$26.8948.75%39.66%
Apr 30, 2026H.C. Wainwright$38.00$26.1145.54%32.68%
Mar 26, 2026Wolfe Research$32.00$26.0322.94%11.73%
Feb 23, 2026Michael SchmidtGuggenheim$40.00$29.2936.57%39.66%
Feb 17, 2026Benjamin JacksonJefferies$41.50$30.0338.20%44.90%
Jan 20, 2026H.C. Wainwright$39.00$32.2520.93%36.17%
Nov 06, 2025Asthika GoonewardeneTruist Financial$48.00$28.8466.44%67.60%
Oct 06, 2025Asthika GoonewardeneTruist Financial$49.00$33.5646.01%71.09%
Oct 02, 2025H.C. Wainwright$40.00$31.7725.90%39.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 22, 2026Cowen & Co.HoldBuyupgrade
Jul 02, 2026H.C. WainwrightBuyBuyhold
May 11, 2026Deutsche BankBuyBuyhold
Mar 26, 2026Wolfe ResearchOutperforminitialise
Mar 02, 2026Wells FargoOverweightinitialise
Feb 23, 2026GuggenheimBuyBuyhold
Feb 18, 2026H.C. WainwrightBuyBuyhold
Jan 28, 2026H.C. WainwrightBuyBuyhold
Jan 06, 2026Deutsche BankBuyBuyhold
Jan 06, 2026BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

$0 $14 $28 $42 $56 $70 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.60$8.45$66.64-----
Avg Forecast$4.37$9.88$7.48$8.66$9.62$12.41$17.92$22.36
High Forecast$4.60$10.45$8.36$9.91$14.02$14.13$20.13$23.89
Low Forecast$4.06$8.83$6.85$7.76$7.48$8.31$15.91$19.63
Surprise %5.26%-14.47%790.91%-----

Revenue Forecast

$5B $13B $21B $29B $37B $45B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.48B$14.60B$16.47B-----
Avg Forecast$8.39B$14.05B$16.16B$21.64B$25.39B$29.23B$33.61B$39.61B
High Forecast$8.74B$14.68B$16.44B$22.57B$26.31B$29.40B$33.81B$41.70B
Low Forecast$7.94B$12.91B$15.89B$20.78B$24.04B$29.06B$33.41B$35.89B
Surprise %1.10%3.89%1.92%-----

Net Income Forecast

$0 $4B $8B $12B $16B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.96B$5.45B$4.35B-----
Avg Forecast$15.19B$14.90B$4.35B$582.45M$708.62M$739.70M$1.19B$1.47B
High Forecast$18.22B$17.88B$5.22B$653.26M$924.29M$931.50M$1.33B$1.57B
Low Forecast$12.15B$11.92B$3.48B$511.65M$492.95M$547.90M$1.05B$1.29B
Surprise %-80.53%-63.41%------

GMAB Forecast FAQ

Is Genmab stock a buy?

Genmab stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Genmab is a favorable investment for most analysts.

What is Genmab's price target?

Genmab's price target, set by 18 Wall Street analysts, averages $39.08 over the next 12 months. The price target range spans from $32 at the low end to $43 at the high end, suggesting a potential 36.45% change from the previous closing price of $28.64.

How does Genmab stock forecast compare to its benchmarks?

Genmab's stock forecast shows a 36.45% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Genmab over the past three months?

  • July 2026: 0% Strong Buy, 81.82% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 0% Strong Buy, 81.82% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 0% Strong Buy, 81.82% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.

What is Genmab’s EPS forecast?

Genmab's average annual EPS forecast for its fiscal year ending in December 2024 is $8.66, marking a -87.00% decrease from the reported $66.64 in 2023. Estimates for the following years are $9.62 in 2025, $12.41 in 2026, $17.92 in 2027, and $22.36 in 2028.

What is Genmab’s revenue forecast?

Genmab's average annual revenue forecast for its fiscal year ending in December 2024 is $21.64B, reflecting a 31.37% increase from the reported $16.47B in 2023. The forecast for 2025 is $25.39B, followed by $29.23B for 2026, $33.61B for 2027, and $39.61B for 2028.

What is Genmab’s net income forecast?

Genmab's net income forecast for the fiscal year ending in December 2024 stands at $582.45M, representing a -86.62% decrease from the reported $4.35B in 2023. Projections indicate $708.62M in 2025, $739.7M in 2026, $1.19B in 2027, and $1.47B in 2028.